cp wire

CP Wire Articles

Pfizer Inc. (NYSE:PFE) announced on 6/1/2018 the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing... read more

Fri, 06/1/18 - 09:56 am
admin
  • 10 new cohorts added
  • 8 cohorts added in January of 2018
  • Trial could include up to 640 patients total


Exelixis, Inc. (Nasdaq:EXEL) announced on 6/1/2018 an... read more

Fri, 06/1/18 - 09:37 am
admin

Siolta Therapeutics is focused on treating inflammatory and allergic diseases via live biotherapeutics (LBTs) to improve the functioning of the gut microbiome. They are working to develop... read more

Thu, 05/31/18 - 09:59 am
admin

CAMP4 Therapeutics  is on a mission to modernize the way the pharma industry discovers new treatments. Operating at the intersection of biology and computation, CAMP4 is building on seminal... read more

Thu, 05/31/18 - 09:28 am
admin
  • Shares up over 47% in premarket trading
  • vTv will receive upfront payment and is eligible for future milestones and royalties
  • Partner intends to develop COPD treatment... read more
Thu, 05/31/18 - 09:28 am
admin

T2 Biosystems, Inc. (Nasdaq:TTOO) announced on 5/30/18 that it is commencing an underwritten registered public offering of 5,650,000 shares of its common stock. T2 Biosystems also intends to grant... read more

Wed, 05/30/18 - 11:30 am
admin

Neural Analytics, Inc. announced on 5/30/18 that it received FDA 510(k) clearance for its NeuralBot System, a robotic assistance technology which automatically adjusts orientation and position of... read more

Wed, 05/30/18 - 10:45 am
admin

Researchers from The Sport Science Center at Texas Christian University, Texas Health Sports Medicine, and the University of Wisconsin–La Crosse evaluated the usefulness of biomarker testing in... read more

Tue, 05/29/18 - 01:49 pm
admin

Pfizer Inc. (NYSE:PFE) announced on 5/29/18 that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Xalkori (crizotinib) for the treatment of patients with... read more

Tue, 05/29/18 - 10:14 am
admin
  • Bicycle receives milestone payment associated with phase I initiation
  • Expands alliance with ThromboGenics
  • Announced expanded partnership with AstraZeneca on 5/24/18
  • ... read more
Fri, 05/25/18 - 09:11 am
CP Staff
  • Imfinzi has met both primary endpoints in Pacific trial
  • AstraZeneca will seek expanded labeling
  • Imfinzi currently approved for treatment of patients with unresectable Stage... read more
Fri, 05/25/18 - 08:59 am
CP Staff

BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced on 5/24/18 that BioMarin received standard approval from the U.S. Food and Drug Administration (FDA) for Palynziq (pegvaliase-pqpz) Injection... read more

Fri, 05/25/18 - 08:45 am
CP Staff

Bicycle Therapeutics, announced on 5/24/18 that it is expanding its collaboration with AstraZeneca to include additional targets in respiratory and cardio-metabolic diseases.

The original... read more

Thu, 05/24/18 - 09:20 am
CP Staff

Brii Bio announced on 5/24/18 its launch with significant partnerships and financing. Brii Bio aims to accelerate the development and delivery of breakthrough medicines in China through... read more

Thu, 05/24/18 - 09:10 am
CP Staff

The test, which is at the proof-of-concept stage, can rapidly screen a drop of blood for biomarkers of pancreatic cancer. It can provide results in less than an hour. The findings were published... read more

Wed, 05/23/18 - 01:06 pm
CP Staff
  • Dr. Bischofberger was at Gilead Sciences for almost 30 years
  • Kronos completed $18 million seed financing
  • The company is advancing two programs built on its small molecule... read more
Wed, 05/23/18 - 09:52 am
CP Staff

Pfizer Inc. (NYSE:PFE) announced on 5/22/18 that tafamidis received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) for the treatment of patients with transthyretin... read more

Wed, 05/23/18 - 09:36 am
CP Staff

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) confirmed on 5/23/18 that the U.S. Food and Drug Administration (FDA) has extended the goal date of the Biologics License Application (BLA... read more

Wed, 05/23/18 - 09:17 am
CP Staff

Ardelyx, Inc. (Nasdaq: ARDX) announced on 5/22/18 the pricing of an underwritten public offering of 12,500,000 shares of its common stock at a public offering price of $4.00 per share, before... read more

Tue, 05/22/18 - 08:57 pm
CP Staff
  • Elayta currently in phase II testing
  • Has been granted fast track status by the FDA
  • Phase I/IIa trials showed Elayta  significantly reduced concentrations of synapse damage... read more
Tue, 05/22/18 - 11:00 am
CP Staff

Pages

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.